Dana-Farber Cancer Institute
S

Study of Carboplatin plus Nivolumab in Metastatic Triple-Negative Breast Cancer

By Dana-Farber Cancer Institute FEATURING Sara Tolaney
By Dana-Farber Cancer Institute FEATURING Sara Tolaney
5,485 views
September 24, 2019
1 Comment
Login to view comments. Click here to Login

Related Content

AUTOPLAY
London Breast Meeting

London Breast Meeting 2024

Wed, Sep 4, 2024
12:35
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…

Feat. S. Tolaney, H. Rugo
14:16
Dana-Farber Cancer Institute

Year in Review: Breast Cancer

Feat. P. Tarantino
17:20
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…

Feat. P. Tarantino
25:08
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

Feat. S. Tolaney, H. Rugo
10:34
Sara Tolaney

ASCO® 2024 Noteworthy Abstracts in Breast Cancer

Feat. H. Rugo
04:28
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant …

Feat. S. Tolaney
22:34
Dana-Farber Cancer Institute

What's New in Breast Cancer?

Feat. S. Tolaney
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
07:50
Oncology Data Advisor

ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…

Feat. K. Kalinsky
17:35
Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
06:10
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Summary: "Is There a Role for Combining ADCs W…

Feat. S. Tolaney
21:31
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Summary: "Community Oncologists Highlights&quo…

Feat. S. Tolaney, H. Rugo
30:46
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Panel Discussion: "Metastatic Breast Cancer"

Feat. S. Tolaney, H. Rugo
24:36
ESMO 2022 Conference Coverage

ESMO 2022 Breast Cancer Panel Discussion: Practice-Changing Updates

Feat. H. Rugo, J. O'Shaughnessy
21:37
Dana-Farber Cancer Institute

Standard Treatments for HR+/HER2- mBC in 2023

Feat. S. Sammons
29:25
Young Chae

Hyperprogression in Cancer Treated With Immunotherapy

05:35
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "IMpassion132 Trial - Is There a Rol…

Feat. S. Tolaney
12:21
Insights from 2023 SABCS

SABCS 2023 Insights: "How to Treat TNBC"

Feat. P. Sharma
12:24
Stanford Medicine

HR+ mBC: CDK4/6i Progression Management

Feat. M. Dolezal